PPARGC1A and diabetic kidney disease: Bardoxolone methyl, a first-in-class oral Nrf-2 agonist, has been shown to improve kidney function in diabetic nephropathy patients with transcriptional expression of network genes (like as PGC-1α, nuclear respiratory factor-1) that are linked with mitochondrial function25.